Morgan Stanley analyst Erin Wright initiated coverage of Molina Healthcare (MOH) with an Overweight rating and $364 price target While “varying permutations of policy headwinds are looming” across Medicaid, the overhang is disproportionately reflected in Molina at “trough valuations,” the analyst tells investors in a research note. The firm sees a strengthening Medicaid footprint and dual eligible integration potential for the company. Policy risk is a key variable but could be more manageable than feared, contends Morgan Stanley. While the Medicaid sector is not without risk, the overhangs are largely reflected in valuations at 10-year troughs, on average, contends the firm.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOH:
- Trump Trade: Tesla bouncing back after $152B in market cap loss amid Musk spat
- Senate Republicans consider Medicare spending cuts, Bloomberg says
- Trump Trade: Trump says Fed ‘must now’ lower rates after jobs report
- Trump conceals Medicaid cuts in effort to pass major tax bill, Bloomberg says
- Molina Healthcare price target lowered to $351 from $362 at Barclays
